Sunshine Biopharma closes $6M public offering with warrant upside

Sunshine Biopharma Inc. (NASDAQ: SBFM) has closed a public offering that generated approximately $6.0 million in gross proceeds, before placement agent fees and other expenses, according to a press release.

The offering consisted of 10,909,082 Common Units or Pre-Funded Units, priced at $0.55 per Common Unit. Each unit included one share of common stock or one Pre-Funded Warrant, along with two Series D Warrants to purchase one share of common stock at an exercise price of $0.66 per share.

The Series D Warrants are exercisable immediately and expire five years from the date of issuance. If fully exercised on a cash basis, they could generate an additional $14.4 million in gross proceeds, bringing the total potential proceeds to approximately $20.4 million. The company stated that no assurance can be given that any warrants will be exercised.

The company said it intends to use net proceeds for general corporate purposes and working capital.

Aegis Capital Corp. served as the exclusive placement agent for the offering. The registration statement was declared effective by the U.S. Securities and Exchange Commission on October 7, 2026.

Sunshine Biopharma markets 61 generic prescription drugs in Canada and is developing two proprietary drug candidates: an mRNA-based therapeutic targeting liver cancer and a small-molecule antiviral for SARS-related coronavirus infections.

You May Also Be Interested In

• Zuckerberg: Meta has reached AI ‘frontier,’ rejects calls for slowdown
• Chilean Cobalt expands NeoRe rare earth project area to 67,400 hectares
• CervoMed reports early biomarker data from nfvPPA drug trial